Results 51 to 60 of about 616,871 (170)

A RUNX2-Mediated Epigenetic Regulation of the Survival of p53 Defective Cancer Cells.

PLoS Genetics, 2016
The inactivation of p53 creates a major challenge for inducing apoptosis in cancer cells. An attractive strategy is to identify and subsequently target the survival signals in p53 defective cancer cells.
Min Hwa Shin, Yunlong He, Eryney Marrogi, Sajida Piperdi, Ling Ren, Chand Khanna, Richard Gorlick, Chengyu Liu, Jing Huang   +8 more
doaj   +1 more source

“Precision Targeted and Combination Therapies in AML: Confronting Resistance with Multi-Pathway Inhibition” [PDF]

Archives of Pharmaceutical Sciences Ain Shams University
Acute myeloid leukemia (AML) is a genetically complex and heterogeneous aggressive cancer in which targeted therapies have improved outcomes but are often limited by induced resistance.
Elmenier, Fatma M., Dokla, Eman M., Samir, Nermin, Lasheen, Deena S., Abouzid, Khaled A. M., Aboul Ella, Dalal Abdelrahman   +5 more
doaj   +1 more source

Menin inhibitor MI-503 exhibits potent anti-cancer activity in osteosarcoma

Scientific Reports
Small molecule Menin inhibitor recently has emerged as a new therapeutic by targeting the interaction of histone methyltransferase MLL1 (KMT2A) with Menin. MLL1 is associated with aggressive osteosarcoma (OS) in young adults.
Shen Tian, Zhuang-Yu Hao, Deng-Hui Xu, Xuan-Zong Wang, Cheng-Cheng Shi, Yi Zhang   +5 more
doaj   +1 more source

Comprehensive characterization of VSIR reveals dual epigenetic regulation and immune landscape across hematological malignancies

Scientific Reports
VISTA (V-domain Immunoglobulin Suppressor of T cell Activation), encoded by VSIR, functions as an inhibitory checkpoint predominantly expressed on myeloid cells.
Zi-jun Xu, Xiao-mei Wu, Ran Chang, Hao-yu Cao, Fei Wang, Xiang-mei Wen, Jing‑dong Zhou, Jiang Lin, Jun Qian   +8 more
doaj   +1 more source

MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia

Cell Reports, 2017
Summary: Understanding the underlying molecular mechanisms of defined cancers is crucial for effective personalized therapies. Translocations of the mixed-lineage leukemia (MLL) gene produce fusion proteins such as MLL-AF4 that disrupt epigenetic ...
Jon Kerry, Laura Godfrey, Emmanouela Repapi, Marta Tapia, Neil P. Blackledge, Helen Ma, Erica Ballabio, Sorcha O’Byrne, Frida Ponthan, Olaf Heidenreich, Anindita Roy, Irene Roberts, Marina Konopleva, Robert J. Klose, Huimin Geng, Thomas A. Milne   +15 more
doaj   +1 more source

Theoretical models of inhibitory activity for inhibitors of protein–protein interactions: targeting menin–mixed lineage leukemia with small molecules

, 2017
A computationally affordable, non-empirical model based on electrostatic multipole and dispersion terms successfully predicts the binding affinity of inhibitors of menin–MLL protein–protein interactions.
Tomasz Cierpicki, Edyta Dyguda-Kazimierowicz, Szymon Kłossowski, Trupta Purohit, Jolanta Grembecka, Wiktoria Jedwabny   +5 more
core   +1 more source

Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies

Cells
Next-generation sequencing of samples from patients with acute myeloid leukemia (AML) has revealed several driver gene mutations in adult AML. However, unlike other cancers, AML is defined by relatively few mutations per patient, with a median of 4–5 ...
Tiffany Nong, Shefali Mehra, Justin Taylor   +2 more
doaj   +1 more source

Dysregulation of HOXA genes in acute myeloid leukemia and targeted therapy

npj Precision Oncology
The abnormal expression of the HOXA genes is intricately associated with the pathogenesis and progression of acute myeloid leukemia (AML), as these genes are crucial in regulating cellular differentiation and proliferation during normal hematopoiesis. In
Wusixian Huang, Fenghong Zhang, Zhiyu Zhang, Qinrong Wang, Suning Chen   +4 more
doaj   +1 more source

Targeted therapy in KMT2Ar AML

Hematology
Objective This review aims to summarize current progress in targeted therapy for acute myeloid leukemia (AML) with KMT2A rearrangement (KMT2Ar). This subtype of AML often shows resistance to chemotherapy and has a poor prognosis.
Ying Zhang, Yankun Yang, Yiwen Du, Yuqian Tang, Yuping Gong   +4 more
doaj   +1 more source

A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias

Journal of Hematology & Oncology
Several menin inhibitors are in development targeting menin dependent leukemias, however available preclinical results show variable level of activity.
Jayastu Senapati, Marina Konopleva, Ghayas C. Issa, Elias Jabbour, Tapan Kadia, Courtney DiNardo, Gautam Borthakur, Naveen Pemmaraju, Nicholas J. Short, Musa Yilmaz, Indraneel Deshmukh, Joie Alvarez, Sanam Loghavi, Guilin Tang, Hussein A. Abbas, Michael Andreeff, Kapil Bhalla, Narasimha M. Midde, Nabil Said, Amy Noyalis, Derek E. Mires, Jing Ning, Lianchun Xiao, Farhad Ravandi, Guillermo Garcia-Manero, Hagop M. Kantarjian, Naval G. Daver   +26 more
doaj   +1 more source